HK Stock Market Move | IMMUNEONCO-B(01541) rose more than 15% in the afternoon, and data for the IMM2510 combination chemotherapy clinical trial will be released in the second half of the year at the earliest.

IMMUNEONCO-B (01541) rose more than 15% in the afternoon, as of the time of writing, it has risen by 14.4%, to 5.56 Hong Kong dollars, with a transaction amount of 91.407 million Hong Kong dollars. On the news front, IMMUNEONCO-B had previously announced that the Ib/II phase clinical trial of its independently developed IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has successfully completed the first patient dosing. After the safety induction period, the company plans to recruit first-line patients in the above clinical trial, with preliminary clinical data expected to be released as early as the second half of 2025. In addition, IMMUNEONCO-B recently announced that it has sold industrial land located in the Kangqiao Industrial Park in Pudong New Area, Shanghai, with a land area of approximately 28,763 square meters to Zhangjiang Group for a maximum cash consideration of 98.19 million yuan. Furthermore, IMMUNEONCO-B recently completed a placement transaction, raising approximately 230 million Hong Kong dollars, with 70% intended for funding critical clinical research in China, including combination therapy with pembrolizumab and trastuzumab in critical cancer studies; and approximately 30% for general corporate purposes.